Concert Pharmaceuticals, Inc.
Below is a great description of what Concert is all about. The robust pipeline link works and takes you directly to their pipeline chart. The management is top of the line, only worry would be a quick buyout. The board is loaded with flippers that love to sell off what they have started in the past....
They have collaborations with Avinir Pharma, Jazz Pharma, and Celegene Pharma. Have been a public company for only 6 months. Have Revenue already and Avinir just announced that a phase II trial in agitation via ALZ patient had great readings.
Introduction: Building Better Medicines
We are a clinical stage biopharmaceutical company applying its extensive knowledge of deuterium chemistry to discover and develop novel small molecule drugs. Our approach starts with approved drugs, advanced clinical candidates or previously studied compounds that we believe can be improved with deuterium substitution to provide better pharmacokinetic or metabolic properties and thereby enhance clinical safety, tolerability or efficacy. We have executed on this approach to become a clinical stage biotechnology company and are developing a robust pipeline of product candidates in several therapeutic areas.
We apply our DCE Platform to systematically identify approved drugs, advanced clinical candidates or
previously studied compounds that we believe can be improved with deuterium substitution. Potential
advantages of our selective deuteration include:
- Improved metabolic profile. We have selectively deuterated compounds and compounds produced by
metabolism of other compounds, which are called metabolites, to improve their metabolic profiles by
reducing the formation of toxic or reactive metabolites or by increasing the formation of desired,
active metabolites relative to the corresponding non-deuterated compound. The improved metabolic
profile may potentially reduce or eliminate unwanted side effects or undesirable drug interactions.
Improved oral bioavailability. We have selectively deuterated compounds to reduce the extent of
undesired metabolism in the wall of the intestines and in the liver, referred to as first-pass metabolism. This resulted in a larger percentage of unmetabolized drug reaching the target site of action. Deuterated compounds with improved bioavailability may be active at lower doses.
Increased half-life.We have selectively deuterated compounds to prolong their pharamacokinetic
profile, which is an increase in the half-life of the compound in the body. This may decrease the
number of doses that a patient is required to take per day or provide more consistent exposure of the compound in comparison to the corresponding non-deuterated compound.
DCE Platform® - More Efficient and Less Expensive
Unlike traditional methods of drug discovery which involve lengthy processes with high failure rates, our approach generally begins with approved drugs, advanced clinical compounds or previously studied compounds. We prioritize candidate compounds based on medical need, commercial opportunity, competitive and patent landscapes and internal strategic fit. We believe our approach may enable drug discovery and clinical development that is more efficient and less expensive than conventional small molecule drug research and development.
A Novel Drug Discovery Paradigm
The average adult human body contains approximately two grams of deuterium. While essentially
identical to hydrogen in size and shape, deuterium differs from hydrogen in that it contains an additional
neutron. As a result, deuterium forms a more stable chemical bond with carbon than does hydrogen. The
deuterium-carbon bond is typically six to nine times more stable than the hydrogen-carbon bond. This
has important implications for drug development because drug metabolism often involves the breaking of
Because deuterium forms more stable bonds with carbon, deuterium substitution can in some cases alter
drug metabolism, including through improved metabolic stability, reduced formation of toxic
metabolites, increased formation of desired active metabolites, or a combination of these effects. At the
same time, because deuterium closely resembles hydrogen, the substitution of deuterium for hydrogen
has generally been found not to materially alter the intrinsic biological activity of a compound.
Deuterated compounds can generally be expected to retain biochemical potency and selectivity similar to
their hydrogen analogs. The effects, if any, of deuterium substitution on metabolic properties are highly
dependent on the specific molecular positions at which deuterium is substituted for hydrogen. In
addition, the metabolic effects of deuterium substitution, if any, are unpredictable, even in compounds
that have similar chemical structures.
A clinical stage biopharmaceutical company, discovers and develops small molecule drugs for central nervous system disorders, renal disease, inflammation, and cancer. The company’s clinical-stage product candidates include CTP-354, which in Phase I clinical trial for spasticity associated with multiple sclerosis and spinal cord injury; CTP-499 that is in Phase II clinical trial for diabetic kidney disease; and AVP-786 for neurologic and psychiatric disorders. Its preclinical compounds comprise CTP-730 for inflammatory diseases; JZP-386, a deuterated analog of sodium oxybate for narcolepsy; and C-10068, an oral deuterium-substituted analog of dextroethorphan, which is used for the treatment of pain and seizure-generating diseases and injuries, such as epilepsy, ischemic stroke, and traumatic brain injury. The company has collaborations with Avanir Pharmaceuticals, Inc., Celgene Corporation, Celgene International Sàrl, and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.(yahoo)